A5063586848- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Psoriasis: Treatment and Pathogenesis
- Health Systems, Economic Evaluations, Quality of Life
- Cytokine Signaling Pathways and Interactions
- Bone and Joint Diseases
- Tuberculosis Research and Epidemiology
- Musculoskeletal synovial abnormalities and treatments
- Viral Infections and Immunology Research
- Pregnancy and Medication Impact
- HER2/EGFR in Cancer Research
- Pharmaceutical studies and practices
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Orthopedic Infections and Treatments
- Galectins and Cancer Biology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Pharmaceutical Economics and Policy
- Mycobacterium research and diagnosis
University of Copenhagen
2016-2025
Rigshospitalet
2016-2025
Center for Rheumatology
2016-2025
Copenhagen University Hospital
2015-2025
Glostrup Hospital
2016-2025
Diakonhjemmet Hospital
2014-2025
Sørlandet Sykehus
2024
University of Bari Aldo Moro
2024
The Ohio State University
2023
Inserm
2023
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
Abstract Objective To compare tumor necrosis factor α inhibitors directly regarding the rates of treatment response, remission, and drug survival rate in patients with rheumatoid arthritis (RA), to identify clinical prognostic factors for response. Methods The nationwide DANBIO registry collects data on rheumatology receiving routine care. For present study, we included from who had RA (n = 2,326) whom first biologic was initiated (29% received adalimumab, 22% etanercept, 49% infliximab)....
The present study was designed to provide information on the relationship between self-reports of health and physicians' ratings in an aged sample, determine how both these measures relate longevity. Subjects were 69 survivors (median age = 84.25 years) a sample twins who had been followed longitudinally since 1947 1949. Self-reports found be significantly correlated with assigned by physician basis medical records. Both types were-predictive differences survival time among younger subjects...
Objective: To identify predictors of radiographic progression in a 2-year randomised, double-blind, clinical study (CIMESTRA) patients with early rheumatoid arthritis (RA). Methods: Patients RA (n = 130) were treated methotrexate, intra-articular betamethasone and ciclosporin/placebo-ciclosporin. Baseline magnetic resonance imaging (MRI) the wrist (wrist-only group, n or MRI metacarpophalangeal (MCP) joints (wrist+MCP 89) (OMERACT RAMRIS), x -ray examination hands, wrists forefeet (Sharp/van...
<h3>Background</h3> Biological disease-modifying anti-rheumatic drugs (bioDMARDs) are generally used in combination with conventional synthetic DMARDs (csDMARDs) the treatment of rheumatoid arthritis (RA). Anti-TNF agents more effective csDMARDs (COMBO) than as monotherapy (MONO), while this is debated some newer bioDMARDs.(1) In particular, no difference was found patients (pts) insufficient response to TNF-inhibitors taking abatacept (ABA) MONO vs. COMBO.(2) <h3>Objectives</h3> To compare...
Background During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by presence of symptoms without clinically apparent synovitis. These are not well-characterised. This taskforce aimed define clinical characteristics with arthralgia who considered at risk for RA experts based on their experience. Methods The consisted 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and research fellow. process had three phases. In I, list...
According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic (PsA) and axial spondyloarthritis (AxSpA). We investigated disease activity before/after switching retention rates the DANBIO registry.Disease activities 3 months before after changes over time were calculated. Flare defined as change 28 Joint Disease Activity Score (∆DAS28) ≥1.2 (RA/PsA) or...
Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice patients inflammatory arthritis (IA) and history cancer. To perform systematic literature review to inform Task Force formulating EULAR points consider on the initiation targeted IA Specific research questions were defined within before exact queries librarian. We included studies reporting relative measure cancer initiating therapy or conventional synthetic...
Abstract Objective To investigate disease activity, treatment response, and drug survival, predictors thereof, among Danish patients with psoriatic arthritis (PsA) receiving their first series a tumor necrosis factor α (TNFα) inhibitor. Methods Patients PsA were identified from prospective nationwide rheumatologic database, the biologics registry DANBIO, using data registered 2000–2009. Information was obtained on patients' clinical response to anti‐TNFα (defined as achievement of American...
To conduct a cross-sectional review of non-selected consecutive outpatients with rheumatoid arthritis (RA) as part standard clinical care in 15 countries for an overview the characteristics patients RA.
To use prospectively registered data from the Danish nationwide rheumatological database (DANBIO) to describe disease activity, clinical response, treatment duration and predictors of drug survival (ie, number days individual patients maintained treatment) response among with ankylosing spondylitis (AS) receiving their first series a tumour necrosis factor α (TNFα) inhibitor.842 TNFα inhibitor naive AS were identified in DANBIO. Clinical thereof investigated. 'Clinical response' was defined...
To analyse associations between the clinical status of patients with rheumatoid arthritis (RA) and gross domestic product (GDP) their resident country.The Quantitative Standard Monitoring Patients Rheumatoid Arthritis (QUEST-RA) cohort includes questionnaire data from 6004 who were seen in usual care at 70 rheumatology clinics 25 countries as April 2008, including 18 European countries. Demographic variables, characteristics, RA disease activity measures, score 28 joints (DAS28),...
To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.We conducted an observational cohort study based on Danish nationwide DANBIO registry. Treatment were evaluated using American College Rheumatology criteria for 20% improvement (ACR20)/ACR50/ACR70, European League Against Rheumatism (EULAR) response good response, 28-joint count Disease Activity Score (DAS28)...
<h3>Objective</h3> At 5 years9 follow-up of early (<6 months) rheumatoid arthritis patients to (1) investigate whether initial combination therapy with methotrexate (MTX) and ciclosporin (CSA) (n=80) is superior monotherapy MTX respect prevention radiographic progression, (2) the favourable clinical response reported at 2 years in CIMESTRA trial can be maintained (3) identify predictors outcome. <h3>Methods</h3> 139 completed double-blinding a strict synovitis suppressive treatment...
Running is a popular sport, but in some studies long distance running women has been related to reduced bone mass and potential risk of osteoporosis. To investigate the impact on men, 120 healthy, physically active men (19-56 yr old; 0-160 km/week) were studied. Bone mineral content was measured lumbar spine, total body, proximal femurs by dual energy x-ray absorptiometry forearm single photon absorptiometry. turnover assessed urinary pyridinium cross-links, plasma osteocalcin, serum...
Abstract Objective To investigate whether disease control can be achieved in early active rheumatoid arthritis (RA) by treatment with methotrexate and intraarticular betamethasone, the addition of cyclosporine to regimen has any additional effect. Methods Patients (n = 160) were randomized receive 7.5 mg/week plus 2.5 mg/kg body weight/day (combination therapy) or placebo‐cyclosporine (monotherapy). At weeks 0, 2, 4, 6, 8 every 4 thereafter, betamethasone was injected into swollen joints...
Abstract Objective To compare the performance of different definitions remission in a large multinational cross‐sectional cohort patients with rheumatoid arthritis (RA). Methods The Questionnaires Standard Monitoring Patients RA (QUEST‐RA) database, which (as January 2008) included 5,848 receiving usual care at 67 sites 24 countries, was used for this study. were clinically assessed by rheumatologists and completed 4‐page self‐report questionnaire. database analyzed according to following...
<h3>Objectives</h3> Some studies have reported a possible association between exposure to tumour necrosis factor (TNF) inhibitors and an increased risk of melanoma. The aim this study was investigate the incidence invasive cutaneous melanomas in patients with rheumatoid arthritis (RA) treated TNF (TNFi), other biologic disease modifying drugs non-biologic therapy. <h3>Methods</h3> Eleven registers from nine European countries participated collaborative project. According predefined...
<h3>Background/purpose</h3> Early diagnosis of inflammatory rheumatic diseases is important in order to improve long-term outcome. We studied whether delay (time between onset symptoms and establishment diagnosis) patients with rheumatoid arthritis (RA), psoriatic (PSA) ankylosing spondylitis (AS) changed from year 2000 2011. <h3>Methods</h3> Month initial diagnosis, gender, hospital, birth date first data entry were obtained for 13 721 RA, PSA or AS who had been registered the DANBIO...
<h3>Objectives</h3> To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I). <h3>Methods</h3> Arthritis from DANBIO database were followed-up for Danish Cancer Registry during 2000–2008. <h3>Results</h3> Hazard ratio overall was 1.02 (95% confidence interval (CI) 0.80-1.30) 3347 TNF-I-treated RA compared to non-treated. Excess among found colon (HR 3.52 (95%CI 1.11-11.15), whereas 6 and 0 ovarian cases observed non-treated patients,...
<h3>Aim</h3> To monitor joint inflammation and destruction in rheumatoid arthritis (RA) patients receiving adalimumab/methotrexate combination therapy using MRI ultrasonography. assess the predictive value of ultrasonography for erosive progression on CT compare MRI/ultrasonography/radiography erosion detection/monitoring. <h3>Methods</h3> Fifty-two biological-naive RA were followed with repeated (0/6/12 months) clinical/biochemical assessments during therapy. <h3>Results</h3> No overall or...